{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:44:37Z","timestamp":1792784677279,"version":"4.5.0"},"reference-count":32,"publisher":"American Chemical Society (ACS)","issue":"24","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Laboratory Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The PI3K\/AKT\/mTOR pathway drives fibrotic progression in idiopathic pulmonary fibrosis (IPF). Our design strategy yielded a series of novel imidazo[1,2-b]pyridazine-based dual PI3K\/mTOR inhibitors. Guided by molecular docking, structural optimization introduced phenolic hydroxyl and carboxylic acid groups, enhancing binding and antifibrotic abilities. Compound 11 exhibited potent inhibition (94.9% PI3K\u03b1, 42.99% mTOR at 1 nM) and nanomolar antiproliferative effects in pulmonary fibroblasts (IC50 = 0.380 and 0.090 \u03bcM). In a bleomycin-induced pulmonary fibrosis model, compound 11 (15 mg\/kg) reduced Ashcroft scores, hydroxyproline content, and collagen deposition while restoring lung architecture. Western blot analysis confirmed the downregulation of fibrosis-related proteins. Treated mice showed steady weight recovery. Besides, toxicity test results showed no distinct liver and kidney toxicity in 11-treated mice at therapeutic doses. This work identifies a promising IPF therapeutic lead and establishes a framework for optimizing imidazo[1,2-b]pyridazine scaffolds in antifibrotic drug development.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c02587","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T09:51:48Z","timestamp":1765792308000},"page":"26418-26431","source":"Crossref","is-referenced-by-count":1,"title":["Discovery of Imidazo[1,2-\n                    <i>b<\/i>\n                    ]pyridazine Derivatives as Potent PI3K\/mTOR Dual Inhibitors\nfor the\nTreatment of Pulmonary Fibrosis"],"prefix":"10.1021","volume":"68","author":[{"given":"Wanjing","family":"Zeng","sequence":"first","affiliation":[{"name":"East China Normal University , , ,","place":["Shanghai, China, 200062"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Hua","sequence":"additional","affiliation":[{"name":"East China Normal University , , ,","place":["Shanghai, China, 200062"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Wang","sequence":"additional","affiliation":[{"name":"East China Normal University , , ,","place":["Shanghai, China, 200062"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyin","family":"Li","sequence":"additional","affiliation":[{"name":"East China Normal University , , ,","place":["Shanghai, China, 200062"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yin","sequence":"additional","affiliation":[{"name":"East China Normal University , , ,","place":["Shanghai, China, 200062"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-9726","authenticated-orcid":true,"given":"Xu-wen","family":"Li","sequence":"additional","affiliation":[{"name":"Bohai Rim Advanced Research Institute for Drug Discovery , , ,","place":["Yantai, China, 264117"]},{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences , , ,","place":["Shanghai, China, 201203"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6716-6115","authenticated-orcid":true,"given":"Suzhen","family":"Dong","sequence":"additional","affiliation":[{"name":"East China Normal University , , ,","place":["Shanghai, China, 200062"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-6748","authenticated-orcid":true,"given":"Mingliang","family":"Ma","sequence":"additional","affiliation":[{"name":"East China Normal University , , ,","place":["Shanghai, China, 200062"]},{"name":"East China Normal University , , ,","place":["Shanghai, China, 200062"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2026072715473946300_cit1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor\nin idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J.\nMed."},{"key":"2026072715473946300_cit2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/s2213-2600(17)30207-2","article-title":"Frequency of exacerbations in patients\nwith chronic obstructive pulmonary disease: an analysis of the SPIROMICS\ncohort","volume":"5","author":"Han","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"2026072715473946300_cit3","first-page":"S195","article-title":"Overview\nof idiopathic pulmonary fibrosis, evidence-based guidelines, and recent\ndevelo pments in the treatment landscape","volume":"25","author":"Glassberg","year":"2019","journal-title":"Am.\nJ. Manag. Care"},{"key":"2026072715473946300_cit4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000504763","article-title":"Idiopathic pulmonary fibrosis: best\npractice in monitoring and managing a relentless fibrotic disease","volume":"99","author":"Wuyts","year":"2020","journal-title":"Respiration"},{"key":"2026072715473946300_cit5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12931-019-1093-z","article-title":"Pirfenidone\nattenuates lung fibrotic fibroblast responses\nto transforming growth factor-\u03b21","volume":"20","author":"Jin","year":"2019","journal-title":"Respir.\nRes."},{"key":"2026072715473946300_cit6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/14656566.2018.1425681","article-title":"Nintedanib\nfor the treatment of idiopathic pulmonary fibrosis","volume":"19","author":"Varone","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"2026072715473946300_cit7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone:\nMolecular mechanisms\nand potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2026072715473946300_cit8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/0897190017735242","article-title":"Nintedanib\nfor idiopathic pulmonary fibrosis","volume":"32","author":"Tepede","year":"2019","journal-title":"J. Pharm.\nPract."},{"key":"2026072715473946300_cit9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","article-title":"American Thoracic Society; European\nRespiratory Society; American College of Chest Physicians. Idiopathic\npulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis\nand implications for therapy","volume":"134","author":"Selman","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"2026072715473946300_cit10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12916-015-0412-6","article-title":"Why do patients get\nidiopathic pulmonary fibrosis? Current concepts\nin the pathogenesis of pulmonary fibrosis","volume":"13","author":"Bellaye","year":"2015","journal-title":"BMC\nMed."},{"key":"2026072715473946300_cit11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/jcm6010002","article-title":"A systematic\nreview of the role of\ndysfunctional wound healing in the pathogenesis and treatment of idiopathic\npulmonary fibrosis","volume":"6","author":"Betensley","year":"2017","journal-title":"J. Clin. Med."},{"key":"2026072715473946300_cit12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1183\/09031936.00069307","article-title":"Idiopathic pulmonary fibrosis\/multiple\ncauses and multiple mechanisms?","volume":"30","author":"Maher","year":"2007","journal-title":"Eur. Respir.\nJ."},{"key":"2026072715473946300_cit13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1021\/acs.jmedchem.6b00935","article-title":"Idiopathic\npulmonary fibrosis: current\nstatus, recent progress, and emerging targets","volume":"60","author":"Liu","year":"2017","journal-title":"J. Med. Chem."},{"key":"2026072715473946300_cit14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.matbio.2018.03.021","article-title":"Idiopathic\npulmonary fibrosis: epithelial-mesenchymal\ninteractions and emerging therapeutic targets","volume":"71\u201372","author":"Hewlett","year":"2018","journal-title":"Matrix Biol."},{"key":"2026072715473946300_cit15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.rmed.2017.07.062","article-title":"Therapeutic targets\nin idiopathic\npulmonary fibrosis","volume":"131","author":"Kolb","year":"2017","journal-title":"Respir. Med."},{"key":"2026072715473946300_cit16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.23866\/BRNRev:2017-0003","article-title":"Idiopathic pulmonary\nfibrosis: clinical behavior, pathogenic mechanisms\nand therapeutic approach","volume":"1","author":"Selman","year":"2015","journal-title":"Barcelona Respir.\nNetwork Rev."},{"key":"2026072715473946300_cit17","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.3892\/mmr.2018.9423","article-title":"Pirfenidone\nsuppresses TGF-\u03b21-induced\nhuman intestinal fibroblasts activities by regulating proliferation\nand apoptosis via the inhibition of the Smad and PI3K\/AKT signaling\npathway","volume":"18","author":"Sun","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"2026072715473946300_cit18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/labinvest.2013.6","article-title":"PI3K p110\u03b3 overexpression\nin idiopathic pulmonary fibrosis lung tissue and fibroblast cells:\nin vitro effects of its inhibition","volume":"93","author":"Conte","year":"2013","journal-title":"Lab. Invest."},{"key":"2026072715473946300_cit19","doi-asserted-by":"publisher","first-page":"36803","DOI":"10.1074\/jbc.M005912200","article-title":"Phosphatidylinositol\n3-kinase function is required for transforming growth factor beta-mediated\nepithelial to mesenchymal transition and cell migration","volume":"275","author":"Bakin","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2026072715473946300_cit20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic\nactivities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"2026072715473946300_cit21","doi-asserted-by":"publisher","first-page":"10431","DOI":"10.1158\/0008-5472.CAN-05-1522","article-title":"Transforming growth factor-beta activation\nof phosphatidylinositol\n3-kinase is independent of Smad2 and Smad3 and regulates fibroblast\nresponses via p21-activated kinase-2","volume":"65","author":"Wilkes","year":"2005","journal-title":"Cancer\nRes."},{"key":"2026072715473946300_cit22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as\nregulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev.\nGenet."},{"key":"2026072715473946300_cit23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.apsb.2021.07.023","article-title":"Targeting\nPI3K\/AKT signaling for treatment of idiopathic pulmonary\nfibrosis","volume":"12","author":"Wang","year":"2022","journal-title":"Acta. Pharm. Sin. B."},{"key":"2026072715473946300_cit24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090563","article-title":"Selective\ninhibition of PI3K\/Akt\/mTOR signaling pathway regulates autophagy\nof macrophage and vulnerability of atherosclerotic plaque","volume":"9","author":"Zhai","year":"2014","journal-title":"PLoS One"},{"key":"2026072715473946300_cit25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41467-018-07858-8","article-title":"The mTORC1\/4E-BP1\naxis represents a critical signaling node during fibrogenesis","volume":"10","author":"Woodcock","year":"2019","journal-title":"Nat. Commun."},{"key":"2026072715473946300_cit26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/0008-5472.CAN-08-2146","article-title":"Distinct roles for mammalian target\nof rapamycin complexes in the fibroblast response to transforming\ngrowth factor-beta","volume":"69","author":"Rahimi","year":"2009","journal-title":"Cancer Res."},{"key":"2026072715473946300_cit27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106155","article-title":"A critical\nrole for the mTORC2 pathway in lung fibrosis","volume":"9","author":"Chang","year":"2014","journal-title":"PLoS One"},{"key":"2026072715473946300_cit28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177432","article-title":"Targeting PI3K in cancer treatment:\nA comprehensive\nreview with insights from clinical outcomes","volume":"996","author":"Hossain","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"2026072715473946300_cit29","doi-asserted-by":"publisher","first-page":"1801992","DOI":"10.1183\/13993003.01992-2018","article-title":"A randomised,\nplacebo-controlled\nstudy of omipalisib (PI3K\/mTOR) in idiopathic pulmonary fibrosis","volume":"53","author":"Lukey","year":"2019","journal-title":"Eur. Respir. J."},{"key":"2026072715473946300_cit30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/thoraxjnl-2015-207429","article-title":"Exploration of a potent PI3 kinase\/mTOR inhibitor as\na novel anti-fibrotic agent in IPF","volume":"71","author":"Mercer","year":"2016","journal-title":"Thorax"},{"key":"2026072715473946300_cit31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.115030","article-title":"Function-oriented\nsynthesis of Imidazo[1,2-a]pyrazine and Imidazo[1,2-b]pyridazine derivatives\nas potent PI3K\/mTOR dual inhibitors","volume":"247","author":"Li","year":"2023","journal-title":"Eur. J.\nMed. Chem."},{"key":"2026072715473946300_cit32","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1164\/ajrccm\/140.6.1693","article-title":"An immunohistochemical study of architectural remodeling\nand connective tissue synthesis in pulmonary fibrosis","volume":"140","author":"Kuhn","year":"1989","journal-title":"Am. Rev. Respir. Dis."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c02587","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/24\/26418\/66289580\/acs.jmedchem.5c02587.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/24\/26418\/66289580\/acs.jmedchem.5c02587.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:04:04Z","timestamp":1785182644000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/24\/26418\/5234522\/Discovery-of-Imidazo-1-2-b-pyridazine-Derivatives"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":32,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12,15]]},"published-print":{"date-parts":[[2025,12,25]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02587","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}